Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

fisogatinib (BLU-554)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Blueprint Medicines, CStone Pharma

Drug class:

FGFR4 inhibitor

Related drugs:

FGF19 positive	Hepatocellular Cancer	FGF19 positive	Hepatocellular Cancer	BLU-554 Sensitive: C3 – Early Trials BLU-554 Sensitive : C3	BLU-554 Sensitive: C3 – Early Trials BLU-554 Sensitive : C3
FGF19 negative	Hepatocellular Cancer	FGF19 negative	Hepatocellular Cancer	BLU-554 Resistant: C3 – Early Trials BLU-554 Resistant : C3	BLU-554 Resistant: C3 – Early Trials BLU-554 Resistant : C3
FGF19 overexpression	Hepatocellular Cancer	FGF19 overexpression	Hepatocellular Cancer	BLU-554 Sensitive: C3 – Early Trials BLU-554 Sensitive : C3	BLU-554 Sensitive: C3 – Early Trials BLU-554 Sensitive : C3
FGF19 positive	Hepatocellular Cancer	FGF19 positive	Hepatocellular Cancer	sugemalimab + BLU-554 Sensitive: C3 – Early Trials sugemalimab + BLU-554 Sensitive : C3	sugemalimab + BLU-554 Sensitive: C3 – Early Trials sugemalimab + BLU-554 Sensitive : C3